Microcap Ledger Inogen Inc $INGN
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Orthopedic, Prosthetic & Surgical Appliances & Supplies
- Headquarters
- Beverly, MA
- Fiscal year end
- December 31
- Shares outstanding
- 26,538,337 [10-Q 2026-08-07]
What the company doesAI summary of filing
Inogen is a medical technology company that develops, manufactures, and markets respiratory health products. The company's primary products are portable oxygen concentrators (POCs) sold under the Inogen One and Inogen Rove brands, which deliver supplemental long-term oxygen therapy to patients with chronic respiratory conditions such as COPD. Inogen generates revenue through direct sales to consumers, rentals billed to Medicare and private insurers, and sales to home medical equipment providers and distributors in the United States and 70 countries internationally. The company is revenue-generating and has expanded its product portfolio to include the Simeox airway clearance device (acquired in 2023 and FDA-cleared in December 2024), stationary oxygen concentrators, and CPAP masks through collaborations and acquisitions. [10-K 2026-02-27]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $180.19M | −$12.17M | −$3.74M | $87.28M | [10-Q 2026-08-07] |
| FY ended Dec 2025 | $348.67M | $22.75M | −$11.22M | $103.73M | [10-K 2026-02-27] |
| FY ended Dec 2024 | $335.70M | $35.89M | $5.91M | $113.80M | [10-K 2026-02-27] |
- Quarterly cash burn
- −$1.87M
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-01 | 23,818,413 | [10-Q 2024-11-08] |
| 2025-02-21 | 26,529,544 | [10-K 2025-02-28] |
| 2025-05-02 | 26,887,242 | [10-Q 2025-05-08] |
| 2025-08-01 | 27,040,390 | [10-Q 2025-08-08] |
| 2025-10-31 | 27,148,482 | [10-Q 2025-11-06] |
| 2026-02-20 | 27,232,350 | [10-K 2026-02-27] |
| 2026-05-01 | 27,074,516 | [10-Q 2026-05-08] |
| 2026-08-01 | 26,538,337 | [10-Q 2026-08-07] |
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-01 | Wright Mary E | grant | 1,500 | $5.33 | [4 2026-09-03] |
| 2026-09-01 | Smith Kevin P. | grant | 1,500 | $5.33 | [4 2026-09-03] |
| 2026-09-01 | Smith Kevin P. | exercise | 18,136 | — | [4 2026-09-03] |
| 2026-09-01 | Smith Kevin P. | other | 8,671 | $5.33 | [4 2026-09-03] |
| 2026-09-01 | Smith Kevin Raymond Merrill | grant | 1,500 | $5.33 | [4 2026-09-03] |
| 2026-07-01 | Yi Boyer Jennifer M | sell | 10,938 | $6.60 | [4 2026-07-06] |
| 2026-06-05 | Sahney Mira Kirti | grant | 28,081 | — | [4 2026-06-09] |
| 2026-06-05 | Jamali Vafa | grant | 28,081 | — | [4 2026-06-09] |
| 2026-06-05 | Boehnlein Glenn S | grant | 28,081 | — | [4 2026-06-09] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-30 | 8-K | Material agreement entered; Regulation FD disclosure; Other events |
| 2026-08-07 | 10-Q | Quarterly report |
| 2026-08-06 | 8-K | Results of operations |
| 2026-07-01 | 8-K | Director or officer change; Regulation FD disclosure |
| 2026-06-11 | 8-K | Director or officer change; Shareholder vote results |
| 2026-05-08 | 10-Q | Quarterly report |
| 2026-05-07 | 8-K | Results of operations |
| 2026-04-28 | DEF 14A | Proxy statement |
| 2026-04-17 | PRE 14A | Proxy statement |
| 2026-04-06 | 8-K | Material agreement entered; Director or officer change; Regulation FD disclosure |
| 2026-03-30 | 8-K | Director or officer change; Regulation FD disclosure |
| 2026-03-27 | 13G/A | Beneficial ownership report (5%+ holder) |
Alerts for $INGN
Email me when Inogen Inc files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.